Abstract:Ghrelin is the only known orexigenic gut hormone, and its synthesis, secretion and degradation are affected by different metabolic statuses. This meta-analysis aimed to investigate the potential differences in plasma acyl ghrelin (AG) and des-acyl ghrelin (DAG) concentrations between normal weight and obese adults. Systematic literature searches of PubMed, Embase and Web of Science through October 2021 were conducted for articles reporting AG or DAG levels in obesity and normal weight, and 34 studies with 1863 participants who met the eligibility criteria were identified. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated to evaluate group differences in circulating AG and DAG levels. Pooled effect size showed significantly lower levels of baseline AG (SMD: − 0.85; 95% CI: − 1.13 to − 0.57; P SMD < 0.001) and DAG (SMD: − 1.06; 95% CI: − 1.43 to − 0.69; P SMD < 0.001) in obese groups compared with healthy controls, and similar results were observed when subgroup analyses were stratified by the assay technique or storage procedure. Postprandial AG levels in obese subjects were significantly lower than those in controls when stratified by different time points (SMD 30 min : − 0.85, 95% CI: − 1.18 to − 0.53, P SMD < 0.001; SMD 60 min : − 1.00, 95% CI: − 1.37 to − 0.63, P SMD < 0.001; SMD 120 min : − 1.21, 95% CI: − 1.59 to − 0.83, P SMD < 0.001). In healthy subjects, a postprandial decline in AG was observed at 120 min (SMD: − 0.42; 95% CI: − 0.77 to − 0.06; P SMD = 0.021) but not in obese subjects (SMD: − 0.28; 95% CI: − 0.60 to 0.03; P SMD = 0.074). The mean change in AG concentration was similar in both the obese and lean health groups at each time point (ΔSMD 30min : 0.31, 95% CI: − 0.35 to 0.97, P SMD = 0.359; ΔSMD 60min : 0.17, 95% CI: − 0.12 to 0.46, P SMD = 0.246; ΔSMD 120min : 0.21, 95% CI: − 0.13 to 0.54, P SMD = 0.224). This meta-analysis strengthens the clinical evidence supporting the following: lower baseline levels of circulating AG and DAG in obese individuals; declines in postprandial circulating AG levels, both for the healthy and obese individuals; a shorter duration of AG suppression in obese subjects after meal intake. These conclusions have significance for follow-up studies to elucidate the role of various ghrelin forms in energy homeostasis.

Ghrelin stimulation of growth hormone isoforms: parallel secretion of total and 20-kDa growth hormone and relation to insulin sensitivity in healthy humans

Factors Associated with Fasting Plasma Ghrelin Levels in Children and Adolescents

Circulating Acyl and Des-Acyl Ghrelin Levels in Obese Adults: a Systematic Review and Meta-Analysis

Acute peripheral tissue effects of ghrelin on interstitial levels of glucose, glycerol, and lactate: a microdialysis study in healthy human subjects

198-OR: The Stimulatory Effect of Glucagon on Insulin Secretion Is Glucose Dependent in Healthy Human Subjects

Evidence for Acyl-Ghrelin Modulation of Growth Hormone Release in the Fed State.

Acute Peripheral Metabolic Effects of Intraarterial Ghrelin Infusion in Healthy Young Men

Novel Ghrelin Assays Provide Evidence for Independent Regulation of Ghrelin Acylation and Secretion in Healthy Young Men

Endogenous Ghrelin Levels and Perception of Hunger: A Systematic Review and Meta-Analysis

Age-Dependent Decline in Acyl-Ghrelin Concentrations and Reduced Association of Acyl-Ghrelin and Growth Hormone in Healthy Older Adults

High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans

Impact of Growth Hormone Receptor Blockade on Substrate Metabolism During Fasting in Healthy Subjects.

Changes of Plasma Ghrelin Levels in Children and Adolescents with Growth Hormone Deficiency and Idiopathic Short Stature

Effects of Ghrelin on Hypothalamic Glucose Responding Neurons in Rats

[Ghrelin: beyond hunger regulation]

Final answer: Ghrelin can suppress insulin secretion in humans,but Is It Clinically Relevant?

Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels.

Effects of human pancreatic tumour growth hormone releasing factor on growth hormone and somatomedin C levels in patients with idiopathic growth hormone deficiency

Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans

Changes of Plasma Ghrelin Concentrations During OGTT in Patients with IGR and Type 2 Diabetes Mellitus

Ghrelin Gene‐related Peptides: Multifunctional Endocrine / Autocrine Modulators in Health and Disease